bluuebunny/crossref_metadata_2025_split huggingface dataset:
Effects of fascial abrasion, fasciotomy, and fascial excision on cutaneous wound healing in cats
Authors: Mitsui Akiko , Mathews Kyle G. , Linder Keith E. , Kruse Meghan A. , Roe Simon C. 
Published: March 2009

Abstract
Objective—To evaluate the effects of fascial abrasion, fasciotomy, and fascial excision on cutaneous wound healing in cats.
Animals—Eight 1- to 3-year-old domestic shorthair cats.
Procedures—8 evenly spaced 4-cm2 skin wounds were created on each cat's dorsum, and the underlying subcutaneous tissue was removed to expose the epaxial muscle fascia. Wounds were randomized to receive 1 of 4 treatments (2 wounds/treatment/cat): fascial abrasion, fasciotomy, fascial excision, or control treatment (muscle fascia not disturbed). Bandages were changed and digital photographs and acetate tracings of the wounds were obtained for planimetry daily for 1 week, every other day for 2 weeks, and then every third day for 3 weeks (ie, 40-day observation period). Digitized images were evaluated for granulation tissue formation, wound contraction (surface area measurements), and area of epithelialization.
Results—The epithelialized area and open and total wound areas did not differ among treatments at any time point. Time to the first appearance of granulation tissue was significantly shorter for all treatment groups, compared with that of the control group. Time to achieve granulation tissue coverage of wound base was significantly shorter following fasciotomy (9.6 days) and fascial excision (9.0 days), compared with that of control treatment (18.5 days) or abrasion (16.7 days). Numbers of wounds that developed exuberant granulation tissue following fascial excision (9/16) and control treatment (3/16) differed significantly.
Conclusions and Clinical Relevance—Fasciotomy and fascial excision facilitated early granulation tissue development in cutaneous wounds in cats. In clinical use, these fascial treatments may expedite secondary wound closure or skin grafting.
Estimation of glomerular filtration rate in dogs by plasma clearance of gadolinium diethylenetriamine pentaacetic acid as measured by use of an ELISA
Authors: Nolan Benjamin G. , Ross Linda A. , Vaccaro Dennis E. , Groman Ernest V. , Reinhardt Christopher P. 
Published: March 2009

Abstract
Objective—To evaluate use of gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) to estimate glomerular filtration rate (GFR) by plasma clearance and use of an ELISA as the method of Gd-DTPA quantification.
Animals—16 dogs of various sexes and breeds (12 dogs were clinically normal, and 4 dogs were polyuric and polydipsic with no other clinical or biochemical abnormalities).
Procedures—GFR was estimated by measuring the plasma clearance of Gd-DTPA and iohexol by use of an ELISA and high-performance liquid chromatography (HPLC), respectively. The GFR was determined by use of a 1-compartment model for both methods. The GFRs obtained by Gd-DTPA plasma clearance were compared with those obtained by iohexol plasma clearance by use of correlation analysis, paired t tests, and limits of agreement analysis. A paired t test was used to evaluate differences between the 2 plasma clearance methods.
Results—A strong linear correlation (r2 = 0.90) was found between GFRs derived from the plasma clearance of Gd-DTPA and those derived from the plasma clearance of iohexol. By use of limits of agreement analysis, almost all (13/14) dogs had Gd-DTPA GFRs that were within 12% of iohexol GFRs. The remaining dog had a Gd-DTPA GFR that was 45% higher than the iohexol GFR. There was no significant difference between Gd-DTPA GFRs and those obtained with iohexol.
Conclusions and Clinical Relevance—This study revealed that plasma clearance of Gd-DTPA measured by use of an ELISA is an effective method to estimate GFR in dogs because it compared favorably with results for the iohexol-HPLC method.
How Do Cancer Registries in Europe Estimate Completeness of Registration?
Authors: Blettner M. , Schmidtmann I. 
Published: March 2009

Summary
Objectives: Several methods for estimating completeness in cancer registries have been proposed. Little is known about their relative merits. Before embarking on a systematic comparison of methods we wanted to know which indicators were currently in use and whether there had been comparative investigations of estimation methods.
Methods: We performed a survey among European cancer registries asking which methods for estimating completeness they used and whether they had performed comparisons of methods.
Results: One hundred and ninety-five European cancer registries were contacted after identification using membership directories of the European Network of Cancer Registries (ENCR) and of the International Association of Cancer Registries (IACR). Fifty-six (29%; 22%–36%) of the 195 cancer registries replied. Forty-eight (86%; 74%–94%) of these stated that they estimated completeness. Thirty-five (73%; 58%–85%) used historic comparisons, 31 (65%; 49%–78%) compared their data with a reference registry, 28 (58%; 43%–72%) registries used mortality incidence ratio. Capture-recapture methods were applied in only 12 (25%; 14%-40%) registries. The flow method was used by ten (21%; 10%–35%) registries. There were regional differences in the use of methods. Comparisons of methods were rare and usually restricted to real data at hand. A systematic comparison including all indicators actually in use in cancer registries was not reported.
Conclusions: A comparison of methods under well defined realistic conditions seems to be indicated. Unifying the methods for estimating completeness would improve validity of comparisons between cancer registries.
A Functional Haplotype of PADI4 Gene in Rheumatoid Arthritis: Positive Correlation in a French Population
Authors: GANDJBAKHCH FRÉDÉRIQUE , FAJARDY ISABELLE , FERRÉ BENJAMIN , DUBUCQUOI SYLVAIN , FLIPO RENÉ-MARC , ROGER NADINE , SOLAU-GERVAIS ELISABETH 
Published: March 2009

Objective.A functional haplotype of peptidyl arginine deiminase 4 (PADI4) was associated with susceptibility to rheumatoid arthritis (RA) in Asian populations, but the results are contradictory in Europeans. We investigated (1) the association of 2 single-nucleotide polymorphisms (SNP) located in exon 2 of PADI4 with RA in another Caucasian population; and (2) the association between PADI4 and anti-citrullinated protein (anti-CCP) antibodies.Methods.DNA samples were obtained from 405 French RA patients and 275 controls. All RA patients met the revised criteria of the American College of Rheumatology. PADI4_89 163(G→A) and PADI4_90 245(T→C) SNP were genotyped using a PCR-RFLP method confirmed by direct sequencing. All patients and controls were genotyped for HLA-DRB1. The presence of anti-CCP antibodies was tested in 243 RA patients using an ELISA technique.Results.We focused on PADI4_89 163(G→A) and PADI4_90 245(T→C) SNP that distinguished 2 main haplotypes: AC haplotype (PADI4_89*A PADI4_90*C) and GT haplotype (PADI4_89*G PADI4_90*T), described, respectively, as “nonsusceptible” and “susceptible.” A positive association between RA and presence of the GT haplotype was found in the heterozygous state (p = 0.002) and the homozygous state (RA patients 22%, controls 13%; p = 0.005). A correlation was observed between the presence but not the level of anti-CCP antibodies and the GT heterozygous (p = 0.03) and homozygous (p = 0.05) haplotypes. No correlation was found between the HLA-DRB1 shared epitope and any of the PADI4 haplotypes.Conclusion.Our findings confirm those of Japanese, Korean, and Canadian studies and suggest that PADI4 may be a new susceptibility gene independent of HLA-DRB1 for RA in Caucasian populations.
Changing Patterns of Tumor Necrosis Factor Inhibitor Use in 9074 Patients with Rheumatoid Arthritis
Authors: YAZICI YUSUF , KRASNOKUTSKY SVETLANA , BARNES JAIME P. , HINES PATRICIA L. , WANG JASON , ROSENBLATT LISA 
Published: March 2009

Objective.Patients with rheumatoid arthritis (RA) commonly switch between tumor necrosis factor (TNF) inhibitors after failing to control disease activity. Much of the clinical data that support switching to a second TNF agent when one agent fails to work has come from small, short-term studies. We utilized a US insurance claims database to determine patterns of use such as dose escalation, time to discontinuation, and switching between TNF inhibitors in patients with RA.Methods.A retrospective analysis was performed using an insurance claims database in the US from 2000 to 2005. TNF inhibitor use, time to switch, dose escalation, and continuation times were analyzed in patients with RA.Results.Nine thousand seventy-four patients with RA started TNF inhibitors during the period 2000 to 2005. Etanercept was the most commonly used TNF inhibitor; infliximab had the highest duration of continuation, about 50% at 2 years. In addition, infliximab showed higher rates of dose escalation compared to etanercept and adalimumab. For all TNF inhibitors, time to switching decreased from 2000 to 2005.Conclusion.TNF inhibitor use patterns changed from 2000 to 2005, with more frequent changes among the different TNF inhibitors and a shorter duration of treatment before the change. Only about 50% of TNF inhibitors are still continued at 2 years, reflecting the difference between randomized clinical trials and real-world experience.
Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan
Authors: KOIKE TAKAO , HARIGAI MASAYOSHI , INOKUMA SHIGEKO , INOUE KAZUHIKO , ISHIGURO NAOKI , RYU JUNNOSUKE , TAKEUCHI TSUTOMU , TANAKA YOSHIYA , YAMANAKA HISASHI , FUJII KOICHI , FREUNDLICH BRUCE , SUZUKAWA MICHIO 
Published: March 2009

Objective.Postmarketing surveillance (PMS) was conducted evaluating safety and effectiveness of etanercept (ETN; Enbrel®) in Japan, following all patients with rheumatoid arthritis (RA) during the conditional approval period of ETN.Methods.Registration of patients from 1,334 medical sites was conducted between March 2005 and April 2007. Patients were followed for 24 weeks; data regarding patients’ background, safety, and effectiveness was recorded centrally. Adverse events (AE) and adverse drug reactions (ADR) were coded using the Medical Dictionary for Regulatory Activities. Effectiveness was measured using the Disease Activity Score 28 (DAS28).Results.Of 14,369 patients registered, data collection and evaluation for 7,091 patients by March 2006 is reported. At least 1 AE was observed for 2,173 patients (30.6%); 60% of AE occurred within 8 weeks of starting ETN. Most frequent AE were injection site reaction (n = 377, 5.3%) and rash (n = 228, 3.2%). Serious AE occurred in 403 patients (5.7%); most frequent were pneumonia (n = 59, 0.8%) and interstitial lung disease (n = 42, 0.6%). Pneumonia was the most common specifically important ADR (n = 102, 1.4%). Mean baseline DAS28 was 6.0, which reduced to 4.4 within 4 weeks, and to 3.9 within 24 weeks. The proportion of patients having good or moderate EULAR response measured by DAS28 was 84.1% at Week 24. Effectiveness rates were more favorable in patients concomitantly using methotrexate. Good or moderate EULAR response rate among patients switched from infliximab was 84.9%.Conclusion.This extensive observational trial, including all patients with RA in Japan taking ETN, found ETN to be both effective and well tolerated by Japanese patients with RA. Trial registration: clinicaltrials.gov identifier NCT00503503.
Serum Levels of Soluble CD40 Ligand at Flare and at Remission in Patients with Systemic Lupus Erythematosus
Authors: URQUIZU-PADILLA MARIA , BALADA EVA , CORTÉS FINA , PÉREZ EDUARDO HERMOSILLA , VILARDELL-TARRÉS MIQUEL , ORDI-ROS JOSEP 
Published: March 2009

Objective.To perform a prospective evaluation of soluble CD40 ligand (sCD40L) levels according to the activity of systemic lupus erythematosus (SLE).Methods.Two serum samples were taken from 53 patients with SLE: at flare and at remission. Clinical and biological measures (sCD40L levels were measured by a commercial ELISA) were evaluated in both situations.Results.Patients with SLE had significantly lower median levels of sCD40L during flare than during remission [3365 (6157) vs 7125 (4122) pg/ml; p < 0.001]. The multivariate analysis to explain those patients with lower values of sCD40L during flare than during remission included 3 variables: 2 related to flare (prednisone dose received ≤ 15 mg/day and platelet counts > 192,000 × 106/l) and one related to lower changes in SLE Disease Activity Index (SLEDAI) score. We regrouped patients with the 2 characteristics related to flare as Group 4, and the others were Group 123. All patients with low SLEDAI scores at flare had statistically significant lower sCD40L levels during flare than during remission. When flare SLEDAI scores were higher than the 50th percentile, patients of Group 123 showed the same behavior and even more diminished levels of sCD40L during flare than patients of Group 123 with low SLEDAI scores (p = 0.023); and patients of Group 4 showed no differences in the values of sCD40L between flare and remission (p = 0.241).Conclusion.sCD40L plays a biologically active role, with decreased levels at flare at low SLEDAI scores. At high SLEDAI scores there are mechanisms that involve platelets and that are inhibited by high doses of prednisone that lead to increased serum values of sCD40L at flare.
Quand la variable « femme » ne sera plus significative dans les équations de gains...
Authors: Meurs Dominique , Ponthieux Sophie 
Published: March 2009

Résumé	Dans la logique de l’analyse orthodoxe des déterminants des salaires, le rapprochement des niveaux d’éducation des femmes et des hommes devrait se traduire par un resserrement de l’écart des salaires. Cette prédiction peine à se réaliser : le niveau moyen d’éducation des femmes qui travaillent est supérieur à celui des hommes, mais leurs salaires restent en moyenne inférieurs. L’avantage éducatif n’est en effet pas de taille face aux différences de structure des emplois et de durée de travail, qui expliquent l’essentiel de l’écart des salaires. Ces différences sont liées à des phénomènes de ségrégation, euxmêmes largement issus des comportements sociaux et de la distribution des tâches domestiques et familiales entre les femmes et les hommes.
L'argent du « ménage », qui paie quoi ?
Authors: Roy Delphine 
Published: March 2009

Résumé Loin d’être fondus en un unique « budget du ménage », l’argent de l’homme et celui de la femme restent, dans un couple, différenciés. Une analyse élémentaire des données de l’enquête « Budget des Familles » de l’Insee indique que l’argent des deux conjoints ne sert pas toujours à la même chose : certains postes de dépenses sont clairement sexués. D’un point de vue ethnographique, on observe que l’ampleur et les modalités de la mise en commun des ressources au sein du couple ne vont pas de soi. Le domaine du budget collectif est plus ou moins étendu, et sa négociation explicite, pas toujours possible ni souhaitée. Enfin, dans le cas où la femme gagne moins que l’homme et où il n’y a pas de compte commun, on constate que tous les ménages rencontrés procèdent d’une façon totalement opposée à la notion de « salaire d’appoint » : c’est le « petit » salaire de la femme qui constitue la base de l’argent collectif.
Targeted deletion of the γ‐adducin gene (Add3) in mice reveals differences in α‐adducin interactions in erythroid and nonerythroid cells
Authors: Sahr Kenneth E. , Lambert Amy J. , Ciciotte Steven L. , Mohandas Narla , Peters Luanne L. 
Published: March 2009

AbstractIn red blood cells (RBCs) adducin heterotetramers localize to the spectrin‐actin junction of the peripheral membrane skeleton. We previously reported that deletion of β‐adducin results in osmotically fragile, microcytic RBCs and a phenotype of hereditary spherocytosis (HS). Notably, α‐adducin was significantly reduced, while γ‐adducin, normally present in limited amounts, was increased ∼5‐fold, suggesting that α‐adducin requires a heterologous binding partner for stability and function, and that γ‐adducin can partially substitute for the absence of β‐adducin. To test these assumptions we generated γ‐adducin null mice. γ‐adducin null RBCs appear normal on Wright's stained peripheral blood smears and by scanning electron microscopy. All membrane skeleton proteins examined are present in normal amounts, and all hematological parameters measured are normal. Despite a loss of ∼70% of α‐adducin in γ‐adducin null platelets, no bleeding defect is observed and platelet structure appears normal. Moreover, systemic blood pressure and pulse are normal in γ‐adducin null mice. γ‐ and β‐adducin null mice were intercrossed to generate double null mice. Loss of γ‐adducin does not exacerbate the β‐adducin null HS phenotype although the amount α‐adducin is reduced to barely detectable levels. The stability of α‐adducin in the absence of a heterologous binding partner varies considerably in various tissues. The amount of α‐adducin is modestly reduced (∼15%) in the kidney, while in the spleen and brain is reduced by ∼50% with the loss of a heterologous β‐ or γ‐adducin binding partner. These results suggest that the structural properties of adducin differ significantly between erythroid and various nonerythroid cell types. Am. J. Hematol., 2009. © 2009 Wiley‐Liss, Inc.
Innentitelbild: Perfluoropentaphenylborole (Angew. Chem. 16/2009)
Authors: Fan Cheng , Piers Warren E. , Parvez Masood 
Published: March 2009

AbstractPerfluorarylborane sind eine wichtige Klasse von metallorganischen Lewis‐Säuren, die wie alle perfluorierten Verbindungen besondere Anforderungen an die Synthesemethodik stellen. In ihrer Zuschrift auf S. 2999 ff. beschreiben W. E. Piers et al. die Synthese eines neuen, vollständig fluorierten heterocyclischen Borans, das überdies zur seltenen Verbindungsklasse der antiaromatischen Borole gehört. Die Syntheseroute umfasst normalerweise einfache Transmetallierungen, die durch die elektronenziehenden C6F5‐Gruppen des Produkts verkompliziert werden.magnified image
Tetraazuliporphyrin Tetracation
Authors: Sprutta Natasza , Maćkowiak Stanisław , Kocik Marzena , Szterenberg Ludmiła , Lis Tadeusz , Latos‐Grażyński Lechosław 
Published: March 2009

AbstractAt the crossroads: A unique carbon‐bridged annulene motif—dehydroquatyrin—is imprinted into the molecular structure of the tetraazuliporphyrin tetracation (see picture). The macrocycle, which lies at the intersection of annulene, carbocation, and porphyrin chemistry, is obtained by the standard condensation of azulene and arylaldehyde followed by oxidation. The meso positions of the tetracation are susceptible to anionic or weak nucleophilic attack.magnified image
A rheumatology‐specific informatics‐based application with a disease activity calculator
Authors: Collier Deborah S. , Kay Jonathan , Estey Greg , Surrao Dominic , Chueh Henry C. , Grant Richard W. 
Published: March 2009

AbstractObjectiveTo design a rheumatology‐specific tool with a disease activity calculator integrated into the electronic medical records (EMRs) at our institution and assess physicians' attitudes toward the use of this tool.MethodsThe Rheumatology OnCall (ROC) application culls rheumatology‐pertinent data from our institution's laboratory, microbiology, pathology, radiology, and pharmacy information systems. Attending rheumatologists and rheumatology fellows accessed the ROC and disease activity calculator during outpatient visits at the time of the clinical encounter.ResultsDuring the 12‐week study period, 15 physicians used the ROC application and the disease activity calculator during 474 and 429 outpatient clinic visits, respectively. In weekly survey responses, physicians reported that use of the ROC interface improved patient care in 140 (78%) of 179 visits, and that the Disease Activity Score in 28 joints (DAS28) results at the time of the visit would not have changed patient management in 157 (88%) of these, although seeing a trend in DAS28 was useful in 149 (96%) of 156 visits. At the study's conclusion, most physicians reported that the ROC application was useful (11 of 12 physicians) and that seeing a trend in DAS28 improved daily patient care (12 of 13 physicians).ConclusionThe ROC application is useful in daily rheumatologic care, and the disease activity calculator facilitates management of patients with rheumatoid arthritis. However, widespread acceptance and use of such tools depend upon the general acceptance of and access to EMRs in the clinical setting. The utility of the disease activity calculator may be limited by the lack of available acute‐phase reactant results at the time of the clinical encounter.
Lack of detection of agonist activity by antibodies to platelet‐derived growth factor receptor α in a subset of normal and systemic sclerosis patient sera
Authors: Loizos Nick , LaRiccia Leah , Weiner Jami , Griffith Heather , Boin Francesco , Hummers Laura , Wigley Fredrick , Kussie Paul 
Published: March 2009

AbstractObjectiveTo investigate whether agonist anti–platelet‐derived growth factor receptor α (anti‐PDGFRα) antibodies are present in the serum of patients with systemic sclerosis (SSc; scleroderma).MethodsSera were obtained from healthy subjects and scleroderma patients. An electrochemiluminescence binding assay was performed for detection of serum autoantibodies to PDGFRα, PDGFRβ, epidermal growth factor receptor (EGFR), and colony‐stimulating factor receptor 1 (CSFR1). Serum immunoglobulin was purified by protein A/G chromatography. To assess Ig agonist activity, PDGFRα‐expressing cells were incubated with pure Ig and the level of receptor phosphorylation determined in an enzyme‐linked immunoassay, as well as by Western blotting. Ig agonist activity was also assessed in a mitogenic assay and by MAP kinase activation in a PDGFRα‐expressing cell line.ResultsSera from 34.3% of the healthy subjects and 32.7% of the SSc patients contained detectable autoantibodies to PDGFRα and PDGFRβ, but not EGFR or CSFR1. Purified Ig from these sera was shown to retain PDGFR binding activity and, at 200‐1,000 μg/ml, exhibited no agonist activity in a cell‐based PDGFRα phosphorylation assay and did not stimulate a mitogenic response or MAP kinase activation in a PDGFRα‐expressing cell line. Two purified Ig samples that were unable to bind PDGFRα did exhibit binding activity to a nonglycosylated form of PDGFRα.ConclusionAlthough approximately one‐third of sera from scleroderma patients contained detectable autoantibodies to PDGFR, these antibodies were not specific to scleroderma, since they were also detected in a similar percentage of samples from normal subjects. PDGFRα agonist activity was not demonstrated when purified Ig from these sera was tested in cell‐based assays.